Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): real-world data on survival and safety from the German expanded-access program (EAP)

checkpoint inhibitor, NSCLC, PD-L1, real world, survival

Saved in:

Bibliographic Details
Main Authors:	Faehling, Martin (Author) , Schumann, Christian (Author) , Christopoulos, Petros (Author) , Hoffknecht, Petra (Author) , Alt, Jürgen (Author) , Horn, Marlitt (Author) , Eisenmann, Stephan (Author) , Schlenska-Lange, Anke (Author) , Schütt, Philipp (Author) , Steger, Felix (Author) , Brückl, Wolfgang M. (Author) , Christoph, Daniel C. (Author)
Format:	Article (Journal)
Language:	English
Published:	21 October 2020
In:	Lung cancer Year: 2020, Volume: 150, Issue: 12, Pages: 114-122
ISSN:	1872-8332
DOI:	10.1016/j.lungcan.2020.10.006
Online Access:	Resolving-System, lizenzpflichtig: https://doi.org/10.1016/j.lungcan.2020.10.006
Author Notes:	Martin Faehling, Christian Schumann, Petros Christopoulos, Petra Hoffknecht, Jürgen Alt, Marlitt Horn, Stephan Eisenmann, Anke Schlenska-Lange, Philipp Schütt, Felix Steger, Wolfgang M. Brückl, Daniel C. Christoph

Description
Summary:	checkpoint inhibitor, NSCLC, PD-L1, real world, survival
Item Description:	Gesehen am 04.02.2022
Physical Description:	Online Resource
ISSN:	1872-8332
DOI:	10.1016/j.lungcan.2020.10.006